Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Theodora Mourtzi"'
Autor:
Theodora Mourtzi, Nasia Antoniou, Christina Dimitriou, Panagiotis Gkaravelas, Georgia Athanasopoulou, Panagiota Nti Kostantzo, Olga Stathi, Efthymia Theodorou, Maria Anesti, Rebecca Matsas, Fevronia Angelatou, Georgia Kouroupi, Ilias Kazanis
Publikováno v:
Neural Regeneration Research, Vol 19, Iss 6, Pp 1318-1324 (2024)
[INLINE:1] We have previously shown the neuroprotective and pro-neurogenic activity of microneurotrophin BNN-20 in the substantia nigra of the “weaver” mouse, a model of progressive nigrostriatal degeneration. Here, we extended our investigation
Externí odkaz:
https://doaj.org/article/aa32d554bcdd43c89dff85501112db93
Autor:
Theodora Mourtzi, Ilias Kazanis
Publikováno v:
Neural Regeneration Research, Vol 17, Iss 12, Pp 2637-2642 (2022)
Parkinson’s disease is the second most common neurodegenerative disease and has currently no effective treatment, one that would be able to stop or reverse the loss of dopaminergic neurons in the substantia nigra pars compacta. In addition, Parkins
Externí odkaz:
https://doaj.org/article/9c0dd1b2c1a7426fb39c82861ad2b233
Autor:
Theodora Mourtzi, Dimitrios Dimitrakopoulos, Dimitrios Kakogiannis, Charalampos Salodimitris, Konstantinos Botsakis, Danai Kassandra Meri, Maria Anesti, Aggeliki Dimopoulou, Ioannis Charalampopoulos, Achilleas Gravanis, Nikolaos Matsokis, Fevronia Angelatou, Ilias Kazanis
Publikováno v:
Stem Cell Research & Therapy, Vol 12, Iss 1, Pp 1-18 (2021)
Abstract Background Loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) underlines much of the pathology of Parkinson’s disease (PD), but the existence of an endogenous neurogenic system that could be targeted as a therapeutic
Externí odkaz:
https://doaj.org/article/f5d062c4b66946bbbffd4ae2e394a452
Autor:
Theodora, Mourtzi, Ilias, Kazanis
Publikováno v:
Neural regeneration research. 17(12)
Parkinson's disease is the second most common neurodegenerative disease and has currently no effective treatment, one that would be able to stop or reverse the loss of dopaminergic neurons in the substantia nigra pars compacta. In addition, Parkinson
Autor:
Charalampos Salodimitris, Theodora Mourtzi, Dimitrios Dimitrakopoulos, Dimitrios Kakogiannis, Fevronia Angelatou, Nikolaos Matsokis, Aggeliki Dimopoulou, A. Gravanis, Maria Anesti, Ilias Kazanis, Danai Kassandra Meri, Konstantinos Botsakis, Ioannis Charalampopoulos
Publikováno v:
Stem Cell Research & Therapy
Stem Cell Research & Therapy, Vol 12, Iss 1, Pp 1-18 (2021)
Stem Cell Research & Therapy, Vol 12, Iss 1, Pp 1-18 (2021)
Background Loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) underlines much of the pathology of Parkinson’s disease (PD), but the existence of an endogenous neurogenic system that could be targeted as a therapeutic strategy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::777e45373a14c7c957acf8a306393304
Autor:
Nikolaos Matsokis, Konstantinos Botsakis, Ioannis Charalampopoulos, Katerina Antoniou, Manolis Tzatzarakis, Aggeliki Dimopoulou, Achilleas Gravanis, Georgios T. Stathopoulos, Fevronia Angelatou, Theodora Mourtzi, Nafsika Poulia, Foteini Delis, Vasiliki Panagiotakopoulou
Publikováno v:
Neuropharmacology. 165:107919
BNN-20 is a synthetic microneurotrophin, long-term (P1-P21) administration of which exerts potent neuroprotective effect on the "weaver" mouse, a genetic model of progressive, nigrostriatal dopaminergic degeneration. The present study complements and
Autor:
Ioannis Charalampopoulos, Theodora Mourtzi, Fevronia Angelatou, Nikolaos Panagopoulos, Foteini Delis, Vasiliki Panagiotakopoulou, Christos D. Georgiou, Dimitrios Zisimopoulos, Konstantinos Botsakis, Malamati Vreka, Iosif Pediaditakis, A. Gravanis, Katerina Antoniou, Georgios T. Stathopoulos, Nikolaos Matsokis
Publikováno v:
Neuropharmacology. 121
Neurotrophic factors are among the most promising treatments aiming at slowing or stopping and even reversing Parkinson's disease (PD). However, in most cases, they cannot readily cross the human blood-brain-barrier (BBB). Herein, we propose as a the